Pipeline
Advancing novel precision therapeutics for serious muscle disease
Muscular Dystrophy
| Preclinical | Phase 1 | Phase 2 | Pivotal / Phase 3 |
Regulatory Submission |
Sevasemten is an orally-administered first-in-class fast myosin inhibitor designed to preserve and protect dystrophic muscle against contraction-induced injury in dystrophinopathies including Becker and Duchenne.
Sevasemten is an orally-administered first-in-class fast myosin inhibitor designed to preserve and protect dystrophic muscle against contraction-induced injury in dystrophinopathies including Becker and Duchenne.
Sevasemten is an orally-administered first-in-class fast myosin inhibitor designed to preserve and protect dystrophic muscle against contraction-induced injury in dystrophinopathies including Becker and Duchenne.
Cardiovascular
| Preclinical | Phase 1 | Phase 2 | Pivotal / Phase 3 |
Regulatory Submission |
EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM and other diseases of diastolic dysfunction.
Undisclosed Cardiac SarcomericTarget
Diseases of diastolic dysfunction
Preclinical
EDG-003
Undisclosed Target
Cardiometabolic
Preclinical
*Sevasemten is an investigational therapy that has not been approved for use in Becker muscular dystrophy or Duchenne muscular dystrophy by any regulatory agency, as its safety and effectiveness have not been established for the treatment of these diseases.
**EDG-7500 is an investigational therapy that has not been approved for use in HCM by any regulatory agency, as its safety and effectiveness have not been established for the treatment of these diseases.
Is a clinical trial right for you?
We are currently conducting clinical trials in hypertrophic cardiomyopathy (HCM), as well as Duchenne and Becker muscular dystrophy.
